ZDRAVESKI ZORAN 4

What Happened

• Zoran Zdraveski, Chief Legal and Strategy Officer of TScan Therapeutics (TCRX), received a derivative award on 2026-01-20 covering 350,000 shares. The filing reports an acquisition price of $0.00 (derivative grant), indicating no cash paid at grant.
• The award is an option-style grant (per footnote) that vests over four years: 25% on the one-year anniversary (Jan 20, 2027) and the remainder in equal monthly installments over the next 36 months, subject to continued service.

Key Details

• Transaction date: 2026-01-20; Filing date (Form 4): 2026-01-22 (filed within the typical 2-business-day window).
• Shares/units granted: 350,000 (derivative security reported at $0.00).
• Vesting: 25% at one year, then monthly over 36 months (see footnote F1).
• Shares owned after transaction: Not specified in the provided excerpt.
• Remarks: Filing lists Zdraveski as Chief Legal and Strategy Officer; Exhibit 24 (Power of Attorney) included.

Context

• This was a compensation grant (derivative award), not an open-market purchase or sale. No exercise or sale was reported at the time of this Form 4.
• Such grants are commonly used to align executives’ incentives with shareholder value and require continued service to vest; they are not direct indicators of immediate insider buying/selling intent.